Zhou et al. published an interesting case of a patient with T315I mutant CML lymphoid BC who was treated with CD19 CAR-T therapy and dasatinib achieving a complete molecular remission. Here, CD19 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.